Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Pleomorphic carcinoma of the lung: A surgical outcome

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario,

Neither Maximum Tumor Size nor Solid Component Size Is Prognostic in Part-Solid Lung Cancer: Impact of Tumor Size Should Be Applied Exclusively to Solid.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.

Oncological Characteristics of Radiological Invasive Adenocarcinoma with Additional Ground-Glass Nodules on Initial Thin-Section Computed Tomography:

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non–Small Cell Lung Cancer Aritoshi Hattori, MD,

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma Yasuhiro Tsutani, MD, PhD, Yoshihiro.

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Thymic carcinoma outcomes and prognosis: Results of an international analysis Usman Ahmad, MD, Xiaopan Yao, PhD, Frank Detterbeck, MD, James Huang, MD,

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Erratum Journal of Thoracic Oncology

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Niv Ad, MD, Lawrence M. Wei, MD

Is endoluminal vacuum therapy “sponge worthy”?

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Case reporter's notebook: The who, what, when, where, how, and why of extraction of a benign intracaval tumor Verdi J. DiSesa, MD, MBA The Journal of.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Who is your plastic surgeon

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

“The more things change…”: The challenges ahead

Junaid Haroon, MD, Subroto Paul, MD, MPH

Aritoshi Hattori, MD, Kenji Suzuki, MD

Apples remain apples NO matter what

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Visceral Pleural Invasion Is Not a Significant Prognostic Factor in Patients With a Part- Solid Lung Cancer Aritoshi Hattori, MD, Kenji Suzuki, MD, Takeshi.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD, Takeshi Matsunaga, MD, Kenji Suzuki, MD The Journal of Thoracic and Cardiovascular Surgery Volume 154, Issue 5, Pages 1768-1774.e1 (November 2017) DOI: 10.1016/j.jtcvs.2017.06.062 Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Flowchart show the selection of the study cohort. EGFR, Epidermal growth factor receptor; WT, wild type; TKI, tyrosine-kinase inhibitor. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Overall survival (A) and recurrence-free survival (B) in all patients according to EGFR mutation status. OS, Overall survival; RFS, recurrence-free survival; EGFR, epidermal growth factor receptor; WT, wild type. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Overall survival (A) and recurrence-free survival (B) in patients with EGFR mutated tumors according to EGFR mutation subtype (exon 19 deletions, exon 21 L858R mutation, or other mutations). OS, Overall survival; RFS, recurrence-free survival. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Comparison of overall survival in patients with EGFR mutated tumors who received EGFR-TKI treatment following recurrence and those who did not. EGFR, Epidermal growth factor receptor; TKI, tyrosine-kinase inhibitor. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Overall survival (A) and recurrence-free survival (B) in patients with pathological stage I lung adenocarcinomas according to EGFR mutation status. OS, Overall survival; RFS, recurrence-free survival; EGFR, epidermal growth factor receptor; WT, wild type. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Figure E2 Overall survival (A) and survival periods following recurrence (B) in patients who received epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor TKI treatment according to EGFR mutation subtype (exon 19 deletions, exon 21 L858R mutation, or other mutations). OS, Overall survival. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Improved survival associated with EGFR mutant lung tumors relative to wild-type tumors. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions

Video 1 The importance and relevance of the present study. Video available at: http://www.jtcvsonline.org/article/S0022-5223(17)31574-X/fulltext. The Journal of Thoracic and Cardiovascular Surgery 2017 154, 1768-1774.e1DOI: (10.1016/j.jtcvs.2017.06.062) Copyright © 2017 The American Association for Thoracic Surgery Terms and Conditions